Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vericiguat - Bayer HealthCare Pharmaceuticals/Merck & Co

Drug Profile

Vericiguat - Bayer HealthCare Pharmaceuticals/Merck & Co

Alternative Names: BAY 102; BAY-1021189; MK-1242; VERQUVO

Latest Information Update: 28 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer Bayer HealthCare Pharmaceuticals; Merck & Co
  • Class Amines; Carbamates; Fluorobenzenes; Heart failure therapies; Pyrazoles; Pyridines; Pyrimidines; Small molecules; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic heart failure
  • Phase II Metabolic syndrome
  • No development reported Coronary artery disease

Most Recent Events

  • 20 May 2024 Merck Sharp & Dohme plans a MK-1242-043 phase III trial for Chronic heart failure (In children, In adolescents, In adults, In the elderly) (PO) (NCT06428383)
  • 18 Apr 2024 Bayer initiates enrolment in a phase-II trial for Chronic heart failure in Argentina and USA (PO) (NCT06195930)
  • 06 Apr 2024 Updated efficacy data from a phase III VICTORIA trial presented at the 73rd Annual Scientific Session of the American College of Cardiology (ACC-2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top